Israel Initiates Anti-Dumping Probe into Canadian Medical Cannabis Exports

Canada is once again entangled in a controversy surrounding the export of commercial medical cannabis, as Israel’s Trade Levies Unit launches an “anti-dumping” investigation into the importation of medical marijuana from Canada. The investigation stems from findings of a “causal link” between the imports and adverse effects on Israel’s local cannabis industry, potentially impacting Canada’s substantial cannabis export sector.

The inquiry, initiated in mid-January, raises concerns about potential restrictions on cannabis imports, and its outcome could significantly affect Canada’s fragile cannabis export sector. Israel currently represents over one-third of all cannabis exports from Canada by weight.

In the fiscal year 2023, Israel imported approximately 21,000 kilograms (21 metric tons) of cannabis from Canada for commercial and scientific purposes, according to data from Health Canada. The investigation, driven by reported financial losses among Israeli companies due to competition with affordable Canadian imports, highlights the potential impact on both nations’ cannabis industries.

In a letter to Michael Mancini, chief commercial counselor for the Embassy of Canada in Israel, Danny Tal, director of import administration at Israel’s Ministry of Economy and Industry, announced the anti-dumping investigation. Tal emphasized the importance of information and evidence from interested parties to determine whether dumping occurred, assess consequential injury, and determine the necessary duty.

Global Affairs Canada, which manages the nation’s diplomatic ties, expressed disappointment in Israel’s decision. Agency spokesperson Jean-Pierre Godbout stated, “We are disappointed with Israel’s decision to initiate an anti-dumping investigation on imports of medical cannabis from Canada. We are as well reviewing the details of Israel’s decision and will engage with implicated Canadian exporters.”

The investigation targets ten Canadian companies, including prominent licensed producers such as Canopy Growth (CGC ) Corp., Cronos Group (CRON ), Tilray (TLRY ) Canada, and others. These companies have 30 days to submit relevant information, evidence, and arguments in response to the lengthy questionnaire provided as part of the investigation.

If provisional measures are applied, they will not be determined until at least 60 days after the investigation commences. The probe adds Israel to the list of countries, including Australia, Colombia, and Jamaica, expressing concerns over Canada’s import-export practices related to medical cannabis. The situation underscores the challenges in the limited legal import markets for medical cannabis, with Canada being the largest federally regulated medical market globally, yet not allowing commercial imports.

This story was originally covered by MJBizDaily.